Clinical trial NCT03242993: [18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging
Official title: Biodistribution, Tumor Detection, and Radiation Dosimentry of [18F]-AZAFOL as POSITRON EMISSION TOMOGRAPHY (PET) Tracer in Folate Receptor Positive Cancer Imaging
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Cancer Lung
Metastatic Ovarian Cancer
Lead sponsor: University of Lausanne Hospitals
Sponsor class: OTHER
Collaborators: name: University Hospital, Zürich
name: Cantonal Hospital of St. Gallen
First posted: 2017-08-08
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is a single arm study. No placebo or other comparator will be used. \[18F\]-AzaFol is used as a PET tracer, all patients successfully enrolled will be assigned to the treatment group.
Primary purpose: DIAGNOSTIC

Brief summary: This is a clinical trial category C as this is a first in man trial with an unapproved investigational product. Nevertheless the risk is considered low due to the low dose ≤ 10μg. No toxicity effects were observed preclinically at a dose \>1000 -fold the intended dose. Open-labeled, non-blinded, non-placebo controlled, multicenter study.

Primary objective:

Assessment of biodistribution and FR-specific tumor detection of \[18F\]- AzaFol as a PET imaging agent in patients with FR-positive and FR-negative metastatic cancer of the ovaries or lungs.

Secondary objective:

Calculation of the effective dose to the patient according to the tissue distribution data of \[18F\]-AzaFol (Dosimetry)

Detailed description: Human research study using a radiopharmaceutical product to reveal folate receptor (FR) expression in tumors in patients.

It is known that the FR is overexpressed on a variety of tumor types. FR-positive tumors can be treated with investigational drugs specifically targeting the FR.

Although the FR-expression status may be determined by immunohistochemical staining of tumor biopsies there is a need for a non-invasive method to determine the presence of the FR on primary tumors and metastases in humans. For this purpose a radiopharmaceutical product will be used as a radiotracer. Positron Emission Tomography (PET) is an imaging method which allows assessing the distribution of radiotracers (called PET tracer). With this imaging method it is possible to obtain (semi)quantitative measures of FR-expression on tumors of at least 4-10 mm diameter in patients.

Such a folate-based radiotracer would be a very helpful tool to non-invasively discriminate FR-positive (often found in ovarian and NSC-lung cancer) from FR-negative tumors in patients with cancer disease as this would allow selecting FR-positive patients amenable to FR-targeted therapies, e.g. folate-targeted antimitotic substances such as EC145 VintafolideTM (Endocyte Inc.) or anti-FR-antibodies such as FarletuzumabTM (Morphotek Inc).

Moreover, \[18F\]-AzaFol PET could be used for tumor staging and monitoring therapy as well as for follow-up investigations of patients with FR-positive tumors.

Currently there is a radiopharmaceutical product for research purposes available (99mTc-EC20, EtarfolatideTM, Endocyte Inc.) which can be used for Single Photon Emission Computed Tomography (SPECT) imaging. SPECT, however, has multiple limitations compared to PET, such as inferior spatial resolution, soft tissue attenuation, lack of dynamic acquisition etc. Therefore, a PET-compound for FR imaging has been shown to image FR-positive tumors in experimental animals .

Calculations regarding the incidence and mortality of six frequent cancer types in Switzerland indicate that in over 53% of the new cases the FR is expressed (OncoSuisse, Cancer Statistics 2012).

Investigators demonstrate impressively why FR-targeting emerged as an attractive strategy for tumor diagnosis and for the development of new targeted therapy strategies .

The vitamin folic acid (pteroylglutamic acid) emerged as an almost ideal FR-targeting agent because of the high affine binding to the FR (KD \< 1 nM).

Due to the small size and vitamin character of folic acid, it is non-immunogenic and non-toxic.

In spite of a large number of folate-based nuclear imaging agents which have been developed in the last two decades only one SPECT radiotracer (99mTc-EC20, EtarfolatideTM) is currently being used in clinical trials in the U.S. for SPECT imaging. For over a decade investigators have been focusing research activities on the development of a 18F-based folate radiotracer for PET imaging (13-16). Recently, a novel folate radiotracer has been developed, 3'-aza-3-\[18F\]fluorofolic acid (herein referred to as \[18F\]-AzaFol), for PET imaging purposes.

Compared to SPECT, PET is the more sensitive nuclear imaging method which provides images of an improved resolution and the possibility for accurate quantification of accumulated radioactivity in tumor lesions.

Eligibility criteria: Inclusion Criteria:

* Patients with cancer of the ovaries (adenocarcinoma) or non-small cell lung cancer (adenocarcinoma, squameous cell cancer or other histology) having active tumor with an indication for a systemic treatment in first or further line.
* Last systemic treatment should not applied within 3 weeks before performing study exam
* Male and female patients 18 years and older,
* Voluntarily signed Informed Consent after being informed

Inclusion criteria for \[18F\]-AzaFol PET (enrollment into study):

* FR-positive histology in routinely acquired biopsy samples (30 Patients)
* FR-negative histology in routinely acquired biopsy samples (6 Patients)

Exclusion Criteria:

* contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
* women who are pregnant or breast feeding,
* women with the intention to become pregnant during the course of the study,
* other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease),
* Renal clearance \< 60 mL/min; liver transaminases ≥ 3-fold increased; bilirubin \> 1.5-fold increased; Hb \< 8 g/dl; Tc \< 100'000, ANC \< 1'500/ul
* ECOG 3-4
* known or suspected non-compliance, drug or alcohol abuse,
* inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject,
* Participation in another study with an investigational drug during the present study and 7 days thereafter.
* Enrolment of the investigator, his family members, employees and other dependent persons

Primary outcomes:
measure: SUV values and volume of tracer uptake of all suspected positive lesions
timeFrame: day 0
measure: Potential change of overall staging
timeFrame: day 0
measure: Lesion detection rate in comparison to SOC (CT and/or MR and/or FDG performed within 4 weeks of PET imaging).
timeFrame: day 0
measure: Estimation of gained information using this tracer
timeFrame: day 0
measure: quantitative estimations
timeFrame: day 0
measure: General estimation of gained confidence in changing/adapting therapy based on this image
timeFrame: day 0
measure: Available biopsy results can be used as further variables to better assess the performance of [18F]-AzaFol
timeFrame: day 0
Secondary outcomes:
measure: Calculation of the effective dose to the patient according to the tissue distribution data of [18F]-AzaFol (Dosimetry)
timeFrame: day 0
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Lausanne University Hospitals
state: Vaud
Study officials:
affiliation: Lausanne University Hospitals
name: John Prior, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gnesin S, Muller J, Burger IA, Meisel A, Siano M, Fruh M, Choschzick M, Muller C, Schibli R, Ametamey SM, Kaufmann PA, Treyer V, Prior JO, Schaefer N. Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer. EJNMMI Res. 2020 Apr 8;10(1):32. doi: 10.1186/s13550-020-00624-2.